TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22044609

Group type: EXPERIMENTAL
Intervention: Motivational brief intervention group
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Condoms group
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1115
Study: 19775434

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Usual Care (UC) + Manual Therapy (MT)
Number of subjects: 37
Study: 17119521

Group type: COMPARATOR
Intervention: Walking on land (WL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Swimming (SW)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Walking in water (WW)
Number of subjects: 38
Study: 15010034

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (normal menstruating girls)
Number of subjects: 148
Study: 10653925

Group type: EXPERIMENTAL
Intervention: Aggressive cholesterol-lowering therapy with atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (control)
Number of subjects: 0
Study: 8631186

Group type: EXPERIMENTAL
Intervention: IUD with tailstring
Number of subjects: 22

Group type: COMPARATOR
Intervention: IUD without tailstring
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Copper IUD with polypropylene tailstring
Number of subjects: 22

Group type: COMPARATOR
Intervention: Copper IUD with polyethylene tailstring
Number of subjects: 22
Study: 1658953

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N-9), 150 mg, used cumulatively four times a day for 14 days
Number of subjects: 14
Study: 6623339

Group type: EXPERIMENTAL
Intervention: Neurological examination
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Karnofsky functional rating
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) brain scanning
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 41

Group type: COMPARATOR
Intervention: Karnofsky rating plus neurological examination
Number of subjects: 41

Group type: COMPARATOR
Intervention: CT scan alone
Number of subjects: 41
Study: 31600598

Group type: EXPERIMENTAL
Intervention: XF-73 0.5mg/g 2% gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XF-73 2.0mg/g 2% gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XF-73 0.5mg/g 4% gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4% viscosified placebo gel
Number of subjects: 60
Study: 31226190

Group type: COMPARATOR
Intervention: Conventional implant planning and freehand placement (control group, n = 26)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Stereolithographic guide (T1, n = 24)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 3D‐printed guide (T2, n = 23)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional implant planning and freehand placement (control group)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Stereolithographic guide (T1)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 3D‐printed guide (T2)
Number of subjects: 73
Study: 28365025

Group type: EXPERIMENTAL
Intervention: Prescribed rest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 25032713

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg loading dose, followed by 5 days of 80 mg)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Regular-dose atorvastatin (10 mg)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 218
Study: 24858750

Group type: EXPERIMENTAL
Intervention: 4 mg lycopene/day for 2 weeks with oral prophylaxis (full mouth scaling and root planing completed within 24 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral prophylaxis only
Number of subjects: 20
Study: 21996647

Group type: EXPERIMENTAL
Intervention: Rizatriptan (10 mg oral fast-dissolving tablet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg intravenous infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sumatriptan (6 mg subcutaneous injection)
Number of subjects: 0
Study: 19243818

Group type: EXPERIMENTAL
Intervention: IL-12 300 ng/kg subcutaneously twice weekly for 24 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks (initial treatment)
Number of subjects: 48
Study: 16521225

Group type: EXPERIMENTAL
Intervention: CIFN with polaprezinc 300 mg (regimen A, n=41)
Number of subjects: 83

Group type: COMPARATOR
Intervention: CIFN monotherapy (regimen B, n=42)
Number of subjects: 83
Study: 14709761

Group type: EXPERIMENTAL
Intervention: Women whose partners participated in the interview
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Global severity index measuring total psychological distress
Number of subjects: 172
Study: 11060183

Group type: EXPERIMENTAL
Intervention: Colonoscopy without conscious sedation
Number of subjects: 451
Study: 9103262

Group type: EXPERIMENTAL
Intervention: lyophilic dairy products bulgaricum and biostim (50 g daily for one month)
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 1556540

Group type: EXPERIMENTAL
Intervention: Patient-held minirecord
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (no minirecord)
Number of subjects: 0
Study: 6696322

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3295620

Group type: EXPERIMENTAL
Intervention: Monthly myelosuppressive maintenance chemotherapy after TAD9-induction and consolidation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Double induction followed by consolidation and monthly maintenance
Number of subjects: 81

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 81
Study: 29273245

Group type: EXPERIMENTAL
Intervention: Gonadotrophins plus intrauterine insemination
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Gonadotrophins plus intercourse
Number of subjects: 666

Group type: COMPARATOR
Intervention: Clomifene citrate plus intrauterine insemination
Number of subjects: 666

Group type: COMPARATOR
Intervention: Clomifene citrate plus intercourse
Number of subjects: 666

Group type: COMPARATOR
Intervention: Intrauterine insemination
Number of subjects: 666
Study: 27406394

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily) plus metformin [500 mg twice daily] (VLDM group)
Number of subjects: 3084

Group type: COMPARATOR
Intervention: Metformin uptitration [1000 mg twice daily] (HDM group)
Number of subjects: 3084
Study: 24680621

Group type: EXPERIMENTAL
Intervention: N. sativa oil (2.5ml, two times a day for 2 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (liquid paraffin, 2.5ml, two times a day for 2 months)
Number of subjects: 34
Study: 23440923

Group type: EXPERIMENTAL
Intervention: Real-time alerts based on a predictive algorithm for clinical deterioration.
Number of subjects: 20031
Study: 20414637

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg daily for 6 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19099925

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17255643

Group type: EXPERIMENTAL
Intervention: NeReBot robotic training (about 4 h/week for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard post-stroke multidisciplinary rehabilitation without robotic training
Number of subjects: 20
Study: 12801148

Group type: EXPERIMENTAL
Intervention: Coping skills training group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (conventional discussion)
Number of subjects: 0
Study: 10830451

Group type: EXPERIMENTAL
Intervention: Hypo-osmolar ORS (224 mmol/L)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard ORS (311 mmol/L)
Number of subjects: 70
Study: 8777679

Group type: EXPERIMENTAL
Intervention: High frequency oscillation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 8
Study: 2057035

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Hydralazine (300 mg daily) plus Isosorbide Dinitrate (160 mg daily)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Hydralazine-Isosorbide Dinitrate
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Enalapril and Hydralazine-Isosorbide Dinitrate
Number of subjects: 804
Study: 6648867

Group type: EXPERIMENTAL
Intervention: Hyperventilation challenge
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise challenge
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise following hyperventilation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyperventilation following exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Refractoriness index (exercise first)
Number of subjects: 10
Study: 31215874

Group type: EXPERIMENTAL
Intervention: 18% ethylenediaminetetraacetic acid (EDTA) water solution
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 18% ethylenediaminetetraacetic acid (EDTA) gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 30019676

Group type: EXPERIMENTAL
Intervention: 150 μg iodine/day from a multivitamin supplement for pregnant and lactating women
Number of subjects: 36
Study: 27137626

Group type: EXPERIMENTAL
Intervention: DT+X (spinal cord detethering plus Xiao procedure)
Number of subjects: 20

Group type: COMPARATOR
Intervention: DT (spinal cord detethering only)
Number of subjects: 20
Study: 24317234

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus 0.5% ropivacaine
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0.5% ropivacaine alone
Number of subjects: 62
Study: 23047502

Group type: EXPERIMENTAL
Intervention: Sodium ferulate (SF) 150 mg three times daily for fourteen days
Number of subjects: 19
Study: 19941078

Group type: EXPERIMENTAL
Intervention: Intranasal mometasone
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 18373403

Group type: EXPERIMENTAL
Intervention: Telephone genetic counseling (TGC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional face-to-face genetic counseling
Number of subjects: 0
Study: 16145415

Group type: EXPERIMENTAL
Intervention: PlasmaKinetic surgery
Number of subjects: 101

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 101
Study: 11687568

Group type: EXPERIMENTAL
Intervention: Matrix presentation of survey response options
Number of subjects: 1615

Group type: EXPERIMENTAL
Intervention: Expanded presentation of survey response options
Number of subjects: 1615
Study: 9344829

Group type: EXPERIMENTAL
Intervention: Recombinant human DNase (rhDNase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (without rhDNase)
Number of subjects: 0
Study: 8168887

Group type: EXPERIMENTAL
Intervention: Immobilization in flexion cast
Number of subjects: 98

Group type: COMPARATOR
Intervention: Immobilization in extension cast
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Early mobilization in a sling
Number of subjects: 98

Group type: COMPARATOR
Intervention: Flexion cast
Number of subjects: 98
Study: 2964995

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide and salbutamol therapy (combined)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nebulized ipratropium bromide and salbutamol therapy (separately)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Swimming goggles
Number of subjects: 46

Group type: COMPARATOR
Intervention: Continued antiglaucoma treatment
Number of subjects: 46
Study: 31017585

Group type: EXPERIMENTAL
Intervention: Weekly serial self-measurements of waist and hip circumference combined with motivational text messages for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control messages for 8 weeks
Number of subjects: 60
Study: 26928205

Group type: EXPERIMENTAL
Intervention: Tweet2Quit
Number of subjects: 160
Study: 25842469

Group type: EXPERIMENTAL
Intervention: Rosemary oil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minoxidil 2%
Number of subjects: 100
Study: 23642330

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Anorexia Nervosa (CBT-AN)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 63
Study: 21342066

Group type: EXPERIMENTAL
Intervention: Home-based screening with self-collected urine or vaginal specimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic-based screening
Number of subjects: 0
Study: 20073139

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to improve medication adherence
Number of subjects: 0
Study: 17196664

Group type: COMPARATOR
Intervention: Right unilateral ECT (250% stimulus intensity of titrated threshold)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (150% of threshold)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both treatments (bifrontal and right unilateral ECT)
Number of subjects: 92
Study: 15562054

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural normal saline (Control)
Number of subjects: 30
Study: 11903704

Group type: EXPERIMENTAL
Intervention: Pain Education Programme for district nurses
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 104
Study: 9476461

Group type: EXPERIMENTAL
Intervention: Plasma IL-3 concentrations
Number of subjects: 23

Group type: COMPARATOR
Intervention: Plasma IL-7 concentrations
Number of subjects: 23
Study: 7944874

Group type: EXPERIMENTAL
Intervention: Diagnostic Interview for Genetic Studies (DIGS)
Number of subjects: 0
Study: 3061715

Group type: EXPERIMENTAL
Intervention: Amino acid solution (dilute and hyperosmolar)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hyperosmolar saline solution
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hyperosmolar amino acid solution
Number of subjects: 48
Study: 31953540

Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate (VLC) diet (14%E carbohydrate, <50 g/d; 28%E protein; 58%E fat)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Higher Carbohydrate (HC) diet (53%E carbohydrate; 17%E protein; 30%E fat)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate (VLC) diet
Number of subjects: 84
Study: 29142036

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 or 10 mg twice daily) with concomitant glucocorticoids (GC)
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Tofacitinib (5 or 10 mg twice daily) without concomitant glucocorticoids (GC)
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus glucocorticoids (GC)
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 3200
Study: 27381392

Group type: EXPERIMENTAL
Intervention: MHAA4549A 1.5 mg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MHAA4549A 5 mg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MHAA4549A 15 mg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MHAA4549A 45 mg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MHAA4549A 8,400 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MHAA4549A 10,800 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (trial 1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (trial 2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MHAA4549A
Number of subjects: 35
Study: 25925398

Group type: EXPERIMENTAL
Intervention: Peanut oral escalating immunotherapy (10 mg to 2 g with 2-week increments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peanut oral escalating immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22913981

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21799027

Group type: EXPERIMENTAL
Intervention: Obese children aged 6-11 years
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Obese adolescents aged 12-17 years
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Adults (general population)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Female gender among 12- to 17-year-olds and 18- to 44-year-olds
Number of subjects: 490
Study: 20133267

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: HAART regimen (Control)
Number of subjects: 60
Study: 16710356

Group type: EXPERIMENTAL
Intervention: valsartan plus cilnidipine
Number of subjects: 87

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 87
Study: 15464494

Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate (0.08 microg x kg(‐1) x min(‐1))
Number of subjects: 108
Study: 11762557

Group type: EXPERIMENTAL
Intervention: Ortho Evra contraceptive patch
Number of subjects: 30
Study: 8669219

Group type: EXPERIMENTAL
Intervention: Cimetidine (1200 mg) administered by infusion pump over 24 hrs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine (200 mg) administered by infusion pump over 24 hrs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 2677055

Group type: EXPERIMENTAL
Intervention: Oral flurbiprofen (100 mg/day) + toothbrushing (A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Placebo + toothbrushing (B)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oral flurbiprofen (100 mg/day) only (C)
Number of subjects: 25
Study: 359250

Group type: EXPERIMENTAL
Intervention: 250 mg diflunisal twice daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 37
Study: 31372680

Group type: EXPERIMENTAL
Intervention: Button fixation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Screw fixation
Number of subjects: 30
Study: 30964418

Group type: EXPERIMENTAL
Intervention: Carbendazim resistance (CarR)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Diethofencarb resistance (DieR)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Iprodione resistance (IprR)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Boscalid resistance (BosR)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Benzimidazole-resistant isolates with E198V mutation
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Dual resistance to carbendazim and diethofencarb
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: BosR isolates with H272R mutation
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: IprR isolates
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Triple resistance phenotypes
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: CarR isolates with E198V/K mutations
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Distribution of half maximal effective concentrations
Number of subjects: 257
Study: 28360027

Group type: EXPERIMENTAL
Intervention: Insulin pump treatment
Number of subjects: 317

Group type: COMPARATOR
Intervention: Multiple daily injections
Number of subjects: 317
Study: 25467848

Group type: EXPERIMENTAL
Intervention: PBT2 250 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: PBT2 100 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 24642073

Group type: EXPERIMENTAL
Intervention: Acute nicotine ingestion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22808020

Group type: EXPERIMENTAL
Intervention: Oral rinse (60 seconds with chlorhexidine followed by 60 seconds with nystatin)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No oral rinse
Number of subjects: 220
Study: 21135327

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 17952581

Group type: EXPERIMENTAL
Intervention: Levosimendan (L)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Dobutamine (D)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 88
Study: 15590210

Group type: EXPERIMENTAL
Intervention: HRT every day (0.625 mg CEE and 2.5 mg MPA)
Number of subjects: 137

Group type: COMPARATOR
Intervention: HRT every other day (0.625 mg CEE and 2.5 mg MPA)
Number of subjects: 137
Study: 12199798

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) for 5-7 days
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) reviparin for 5-7 days (short-treated group)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) reviparin for 28 days (long-treated group)
Number of subjects: 1137
Study: 9498541

Group type: EXPERIMENTAL
Intervention: Early postoperative clinical seizures
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Early postoperative EEG seizures
Number of subjects: 171

Group type: COMPARATOR
Intervention: No seizures (control group)
Number of subjects: 171
Study: 8919444

Group type: EXPERIMENTAL
Intervention: Cryotherapy device fitted in the operating room
Number of subjects: 50

Group type: COMPARATOR
Intervention: Noncryotherapy group
Number of subjects: 50
Study: 1811606

Group type: EXPERIMENTAL
Intervention: Intravenous gamma immunoglobulin (IVIG)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 6138116

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 63
Study: 30757935

Group type: EXPERIMENTAL
Intervention: Eclipta prostrata (EP) 1 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eclipta prostrata (EP) 10 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topical 3% minoxidil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 16
Study: 30289329

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) treatment (4 times daily in both eyes for a month before HSCT and continued use after transplantation)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 58